International Journal of Hematology

, Volume 97, Issue 3, pp 351–359 | Cite as

A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers

  • Yoichiro Ogama
  • Tomoko Mineyama
  • Asuka Yamamoto
  • Margaret Woo
  • Naomi Shimada
  • Taro Amagasaki
  • Kazuto Natsume
Original Article

Abstract

Ruxolitinib (INC424), a potent and selective oral Janus kinase 1 and 2 inhibitor, was recently approved by the US food and drug administration for the treatment of intermediate or high-risk myelofibrosis. The safety, tolerability, and pharmacokinetics (PK) of ruxolitinib have been extensively evaluated in healthy subjects and patients. The present study is the first to investigate the PK and tolerability of ruxolitinib in the Japanese population. Forty subjects were randomized to receive single (10–100 mg) and multiple (10 and 25 mg every 12 h) doses of ruxolitinib or placebo. Cohorts were sequentially enrolled based on the outcome of safety assessments. Ruxolitinib was rapidly absorbed, and its exposure increased dose proportionally up to 100 mg. The half-life of ruxolitinib was approximately 3 h, and drug accumulation was not observed after repeated dosing at a 12-h dosing interval. Decreasing absolute neutrophil counts were observed in five Japanese subjects treated once (100 mg, n = 1) or twice (10 mg, n = 3; 25 mg, n = 1) daily. These events were manageable and reversible upon drug discontinuation. Orally administered ruxolitinib was well tolerated in healthy Japanese volunteers. There were no apparent differences in the safety or PK of ruxolitinib between Japanese and non-Japanese subjects.

Keywords

Clinical pharmacokinetics Dose proportionality Oral absorption Race Toxicity 

References

  1. 1.
    Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol Rev. 2009;228:273–87.PubMedCrossRefGoogle Scholar
  2. 2.
    Jatiani SS, Baker SJ, Silverman LR, Reddy EP. JAK/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies genes. Cancer. 2010;1:979–93.Google Scholar
  3. 3.
    Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.PubMedGoogle Scholar
  4. 4.
    Levine RL, Gilliland DG. Myeloproliferative disorders. Blood. 2008;112:2190–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.PubMedCrossRefGoogle Scholar
  6. 6.
    Xiao Z, Zhang Y, Li L, Nie L, Yang L, Xu S. The Janus kinase 2 (JAK2) V617F mutation in Chinese patients with chronic myeloproliferative disorders. Haematologica. 2008;93:787–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Lucia E, Martino B, Mammi C, Vigna E, Mazzone C, Gentile M, et al. The incidence of JAK2 V617F mutation in bcr/abl-negative chronic myeloproliferative disorders: assessment by two different detection methods. Leuk Lymphoma. 2008;49:1907–15.PubMedCrossRefGoogle Scholar
  8. 8.
    Basquiera AL, Soria NW, Ryser R, Salguero M, Moiraghi B, Sackmann F, et al. Clinical significance of V617F mutation of the JAK2 gene in patients with chronic myeloproliferative disorders. Hematology. 2009;14:323–30.PubMedCrossRefGoogle Scholar
  9. 9.
    Quintas-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115:3109–17.PubMedCrossRefGoogle Scholar
  10. 10.
    Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, et al. A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nat Genet. 2009;41:455–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Zhang SJ, Qiu HX, Li JY, Shi JY, Xu W. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay. Int J Lab Hematol. 2010;32:381–6.PubMedCrossRefGoogle Scholar
  12. 12.
    Patnaik MM, Lasho TL, Finke CM, Gangat N, Caramazza D, Siragusa S, et al. MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms. Leukemia. 2010;24:859–60.PubMedCrossRefGoogle Scholar
  13. 13.
    Oh ST, Simonds EF, Jones C, Hale MB, Goltsev Y, Gibbs KD Jr, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010;116:988–92.PubMedCrossRefGoogle Scholar
  14. 14.
    Verstovsek S, Mesa RA, Gotlib JR, Levy RS, Gupta V, DiPersio JF, et al. Results of COMFORT-I, a randomized double-blind phase III trial of JAK 1/2 inhibitor INCB18424 (424) versus placebo (PB) for patients with myelofibrosis (MF). J Clin Oncol. 2011;29:419s [abstract 6500].Google Scholar
  15. 15.
    Harrison CN, Kiladjian J, Al-Ali HK, Gisslinger H, Waltzman RJ, Stalbovskaya V, et al. Results of a randomized study of the JAK inhibitor INC424 compared with best available therapy (BAT) in primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET-MF). J Clin Oncol. 2011;29:782s [abstract LBA6501].Google Scholar
  16. 16.
    Incyte Corporation. JAKAFI prescribing information. 2011. www.jakafi.com. Accessed 16 Aug 2012.
  17. 17.
    Shi JG, Chen X, McGee RF, Landman RR, Emm T, Lo Y, et al. The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers. J Clin Pharmacol. 2011;51:1644–54.PubMedCrossRefGoogle Scholar
  18. 18.
    Shi JG, Chen X, Emm T, Scherle PA, McGee RF, Lo Y, et al. The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers. J Clin Pharmacol. 2012;52:809–18.PubMedCrossRefGoogle Scholar
  19. 19.
    Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between east asians and caucasians and the role of genetic polymorphisms. J Clin Pharmacol. 2004;44:1083–105.PubMedCrossRefGoogle Scholar
  20. 20.
    Tateishi T, Watanabe M, Nakura H, Asoh M, Shirai H, Mizorogi Y, et al. CYP3A activity in european american and japanese men using midazolam as an in vivo probe. Clin Pharmacol Ther. 2001;69:333–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Kinirons MT, Lang CC, He HB, Ghebreselasie K, Shay S, Robin DW, et al. Triazolam pharmacokinetics and pharmacodynamics in caucasians and southern asians: ethnicity and CYP3A activity. Br J Clin Pharmacol. 1996;41:69–72.PubMedCrossRefGoogle Scholar
  22. 22.
    Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176–81.PubMedCrossRefGoogle Scholar
  23. 23.
    Suwa T, Hogg JC, English D, Van Eeden SF. Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol. 2000;279:H2954–60.PubMedGoogle Scholar
  24. 24.
    Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, Thomas DA, et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med. 2010;363:1117–27.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2013

Authors and Affiliations

  • Yoichiro Ogama
    • 1
  • Tomoko Mineyama
    • 1
  • Asuka Yamamoto
    • 1
  • Margaret Woo
    • 2
  • Naomi Shimada
    • 3
  • Taro Amagasaki
    • 3
  • Kazuto Natsume
    • 3
  1. 1.Medical Co. LTA, Sumida HospitalTokyoJapan
  2. 2.Novartis Pharmaceuticals CorporationEast HanoverUSA
  3. 3.Novartis Pharma K.K., Minato-kuTokyoJapan

Personalised recommendations